NGS Platforms and Genomic Analysis to Ensure Transformational Growth of Precision Medicine
Sequencing technologies have evolved over the years to harness the value of the human genome and dive deep into DNA and RNA sequences which offer immense knowledge of human biology. From Sanger sequencing to next-generation sequencing, technologies and chemistries have improved/advanced to reduce costs and ensure faster timelines. NGS has integrated itself into basic life science research to understand disease biology for drug development and diagnostics.
Developments in NGS chemistries such as single-molecule real-time sequencing, sequencing by synthesis, nanopore sequencing, ion and semiconductor technology, in addition to miniaturization of sequencing instrumentation and automation of NGS, boost the adoption of NGS across biological labs. Whole genome sequencing, targeted sequencing, whole exome sequencing, whole transcriptome sequencing, and single-cell RNA sequencing have all found specific applications across omics where they accurately indicate and identify structural variants, SNPs, genetic variations, pathogen detection, patient stratification, drug discovery, and so on.
The NGS market is now witnessing a rise in emerging players that offer improved chemistries and instrumentation to deliver low-cost whole genome sequencing, increasing adoption across geographies and driving precision medicine. Technological advancement of AI-/ML-powered platforms for analyzing sequencing data is helping analyze and interpret large volumes of sequencing data within hours. NGS plays a key role in data-driven clinical medicine and will continue to improve the global healthcare system. The analytics covers developments in NGS and genomic analysis platforms that will make whole genome sequencing more accessible and accelerate early clinical decisions for better health outcomes.
